Medidata's Engage Wins Patient Engagement App Challenge
Medidata's Engage won the Patient Engagement App Challenge (large organization category) at the 23rd Annual Partnerships in Clinical Trials Conference.
Medidata's Engage won the Patient Engagement App Challenge (large organization category) at the 23rd Annual Partnerships in Clinical Trials Conference.
The app prototype is billed as an easy-to-use, device-agnostic app that patients can access via their personal smartphones or other mobile devices.
A team of Medidata engineers developed Engage during company-sponsored innovation time, a program Medidata put in place that allows employees to think creatively about solving problems and use technology in different ways. Engage creates new connections between patients, physicians and sponsors, and is built to work with Medidata Patient Cloud™, a solution for patient-centric data capture and management.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
